MaxCyte, Inc.
MXCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.97 | -0.14 | 1.73 | -2.18 |
| FCF Yield | -6.71% | -5.23% | -5.99% | -1.57% |
| EV / EBITDA | -9.19 | -10.37 | -22.72 | -53.05 |
| Quality | ||||
| ROIC | -22.80% | -19.23% | -10.08% | -6.76% |
| Gross Margin | 81.62% | 88.51% | 88.48% | 89.24% |
| Cash Conversion Ratio | 0.67 | 0.57 | 0.63 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.44% | 6.80% | 19.15% | 16.17% |
| Free Cash Flow Growth | -15.26% | 23.67% | -129.16% | -33.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.63 | -0.20 | 2.53 |
| Interest Coverage | 0.00 | 0.00 | -215.61 | -17.42 |
| Efficiency | ||||
| Inventory Turnover | 0.80 | 0.39 | 0.59 | 0.70 |
| Cash Conversion Cycle | 432.68 | 935.18 | 685.62 | 412.73 |